PharmaCyte Biotech, Inc. 10-Q

Item 5. Other Information . None. 32 Item 6. Exhibits. Exhibit No. Description Location Exhibit No. Description Location 3.1 Certificate of Amendment to Articles of Incorporation, as previously filed as Exhibit 99.1 to the Company’s Current Report on Form 8-K on July 6, 2021 Incorporated by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021 3.2 Certificate of Change to Articles of Incorporation, as previously filed as Exhibit 99.1 to the Company’s Current Report on Form 8-K on July 13, 2021 Incorporated by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021 3.3 Amendment No. 3 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s Current Report on Form 8-K on June 4, 2021 Incorporated by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021 3.4 Amendment No. 4 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s Current Report on Form 8-K on July 6, 2021 Incorporated by reference to the designated exhibit of the Company’s Current Report on Form 10-K filed on August 10, 2021 31.1 Principal Executive Officer Certification required by Rules 13a-14 and 15d-14as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 31.2 Principal Executive Officer Certification required by Rules 13a-14 and 15d-14as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 32.1 Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002 Furnished herewith 32.2 Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002 Furnished herewith 101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101). 33 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. PharmaCyte Biotech, Inc. September 14, 2021 By: /s/ Kenneth L. Waggoner Kenneth L. Waggoner Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) September 14, 2021 By: /s/ Carlos A. Trujillo Carlos A. Trujillo Chief Financial Officer (Duly Authorized Officer and Principal Financial and Principal Accounting Officer) 34